Hemispherx Biopharma, Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
Hemispherx’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
We operate a 30,000 sq. ft. facility in New Brunswick, NJ with the objective of producing Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.
US & Argentina
THOMAS K. EQUELS, M.S., J.D., was named Chief Executive Officer in February 2016, served as President since August 2015, has been a Director since 2008 and presently serves as Hemispherx’ Executive Vice Chairman.
Adam Pascale, CPA
Chief Financial Officer
ADAM PASCALE was named Chief Financial Officer in February 2016, in addition to his current responsibilities as Chief Accounting Officer.
David R. Strayer, M.D.
Chief Scientific & Medical Officer
DAVID R. STRAYER, M.D. was appointed Chief Scientific Officer in Feburary 2016 and has acted served as our Medical Director since 1986. Dr. Strayer, based upon this experience, is the foremost medical expert on Ampligen in the World.
Peter W. Rodino III, J.D.
Executive Director for Governmental Relations, General Counsel, Secretary
PETER W. RODINO, III, Esq., was named Executive Director for Governmental Relations and General Counsel in October 2016 and Secretary of the Company in November 2016.
Chief Accounting Officer
Ellen Lintal joined Hemispherx in 2018 as SVP of Finance and Control after a long and successful accounting career, including nearly a decade with The National Wild Turkey Federation, where she rose to the position of CFO.
Senior Vice President of Operations
WAYNE S. SPRINGATE has served as Senior Vice President of Operations since May 2011 after joining Hemispherx in 2002 as Vice President of Business Development.
Hemispherx Biopharma, Inc.